First-of-its-kind drug aims to protect the heart while increasing effectiveness of cancer treatments

A team of University of Alberta researchers has developed a cardio-oncology drug that protects the heart from chemotherapy damage while enhancing the effectiveness of cancer treatments against tumor growth and spread. In a paper published as the cover story in Science Translational Medicine, the team identifies the target protein ZNF281 and a new drug they've developed called ZIM, or ZNF281 Interfering Molecule.